Advancing <i>Trypanosoma cruzi</i> N-myristoyltransferase as a drug target for Chagas disease through <i>in silico</i> discovery and biochemical evaluation.

ABSTRACT:

Introduction

N-myristoylation is a crucial lipid modification that governs protein localization, intracellular trafficking, and function in eukaryotic cells. The enzyme N-myristoyltransferase (NMT), which catalyzes this modification, has emerged as an attractive drug target for parasitic diseases. In this study, we performed a comprehensive biochemical and antiparasitic evaluation of Trypanosoma cruzi NMT (TcNMT), utilizing novel "in silico-identified inhibitors" to assess its potential as a therapeutic agent for Chagas disease.

Methods

Recombinant TcNMT was cloned, expressed, and purified for enzymatic characterization. Catalytic activity and substrate affinity were evaluated using a fluorescence-based assay. Four in-silico-selected NMT inhibitor

SUBMITTER: Gonzalez Garcia D 

PROVIDER: S-EPMC12816245 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature